Retatrutide, developed by Soma Corp., is receiving increasing attention as a innovative therapy for metabolic regulation. This innovative medication combines the activity of a GLP-1 receptor stimulant and a GIP receptor stimulant, intended to not only promote metabolic improvements but also impro